The Efficacy and Safety of the Xue-Fu-Zhu-Yu Capsule in Treatment of Qi Stagnation and Blood Stasis Syndrome.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-06

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, double-blind, randomized and placebo-controlled trial. The study aims to evaluate the effectiveness and safety of Xue-Fu-Zhu-Yu Capsule (XFZYC) for Qi Stagnation and Blood Stasis syndrome (QS\&BSS). QS\&BSS is one of the common Zhengs in Traditional Chinese Medicine, which manifests as various symptoms and signs, such as distending pain or tingling sensation in a fixed position, irritability or depression, dim complexion, lumps in body, blood spot under the skin, unsmooth or string-like pulse, purplish tongue or petechia in the tongue, etc. In fact, Qi stagnation and blood stasis are common pathological conditions that would occur on human body for several times in the long period of human's life. Besides, QS\&BSS is associated with over 50 kinds of diseases including Coronary Heart Disease, hypertension, cerebral infarction, gastritis, arthritis, dysmenorrhea, chronic pelvic infection, skin disease, and cancer. Xue-Fu-Zhu-Yu Capsule, one of Chinese herbal medicine drugs, could perform the function of promoting Qi and activating blood to relieve the symptoms of QS\&BSS, which was approved by the China Food and Drug Administration in 2002. It has been applied for QS\&BSS since it was recorded in the book Correction on Errors in Medical Classics 200 years ago. In recent years, a number of clinical trials have focused on the effectiveness and safety of XFZYC on patients with QS\&BSS subtype of coronary heart disease, hyperlipidemia, ischemic cerebrovascular disease, gastritis, dysmenorrhea, and arthritis in terms of the outcomes of relevant diseases. Our research group plan this randomized controlled trial to evaluate the effectiveness and safety of Xue-Fu-Zhu-Yu Capsule (XFZYC). A total of 120 patients will be enrolled at the following three hospitals: (1)Guang'anmen Hospital, China Academy of Chinese Medical Sciences, (2)Huguosi TCM Hospital Affiliated to Beijing University of Chinese Medicine, (3)Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China. All participants, with different kinds of disease, will receive the standard medical care according to the guidelines. Participants will undergo a 7-week treatment. The primary outcome is the total score of the Traditional Chinese Medicine Patient Reported Outcome (PRO) Scale in Patients of QS\&BSS; the secondary outcome is the score of the single symptom and sign scale of QS\&BSS and the score of the pain scale of QS\&BSS on the day of enrollment, and at 2nd, 4th, 6th, 7th weeks. Safety outcomes include physical examination (temperature, respiration, heart rate, blood pressure, height and weight); electrocardiogram (ECG); complete blood cell count; coagulation function (prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB), D-Dimer, INR); urinalysis; fecal occult blood test; Liver function (ALT, aspartate aminotransferase (AST), alkaline phosphatase (ALP), serum total bilirubin (STB), and γ-glutamyl transpeptidase (γ-GT)); renal function (Creatinine (Cr), blood urea nitrogen (BUN), and urine N-acetyl-β glucosaminidase) on the day of enrollment, and at 7th weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Xuefu-Zhuyu Capsule for the Treatment of "Qizhi Xueyu Zheng" (Qi Stagnation and Blood Stasis Syndrome)

NCT04218487

Chinese Medicine Stable Coronary Heart Disease Chronic Insomnia +2 more

UNKNOWN PHASE4

A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome)

NCT02875639

Ischemic Heart Failure

UNKNOWN PHASE2

Effects of Yiqi Fuyuan Paste Formula in Chronic Fatigue Syndrome: A Randomized Double-Blind Controlled Clinical Trial.

NCT07320937

CFS

ENROLLING_BY_INVITATION NA

Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis

NCT06933238

Sepsis Abdominal Gastrointestinal Dysfunction Traditional Chinese Medicine

NOT_YET_RECRUITING PHASE1/PHASE2

Evaluating the Safety and Efficacy of Qishen Granules Among Patients With Chronic Heart Failure

NCT03027375

Heart Failure Cardiovascular Diseases

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Qi Stagnation and Blood Stasis Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

test group

the patients in this group take 6 xue-fu-zhu-yu capsules once, twice a day, for 7weeks.

Group Type EXPERIMENTAL

xue-fu-zhu-yu capsule

Intervention Type DRUG

participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks

control group

the patients in this group take 6 xue-fu-zhu-yu capsule simulated agents once, twice a day, for 7weeks..

Group Type PLACEBO_COMPARATOR

xue-fu-zhu-yu capsule simulated agent

Intervention Type DRUG

participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

xue-fu-zhu-yu capsule

participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks

Intervention Type DRUG

xue-fu-zhu-yu capsule simulated agent

participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

xue fu zhu yu capsule simulated agent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The participants diagnosed as QS\&BSS;
* The age of participants is from 18 to 65;
* Participants who voluntarily signed informed consent.

Exclusion Criteria

* Participants with other obvious Chinese medicine syndrome
* Participants diagnosed as acute myocardiac infarction, acute phase of cerebral infarction, aortic dissection and other critically illness;
* Participants with poor control of hypertension (systolic pressure \>160 millimeters of mercury (mmHg) or diastolic blood pressure \>100mmHg), severe heart failure and severe arrhythmia (atrial fibrillation, atrial flutter, ventricular tachycardia, paroxysmal II type II atrioventricular block and complete bundle branch block);
* Participants with severe primary diseases of heart, brain, liver, kidney and hematopoietic system, or liver function ALT or AST value \>1.5 times of the upper limit of the normal value, or abnormal renal function;
* Depression or anxiety disorders participants;
* Pregnant or lactating women;
* Participants with nerve or mental illness, or unwilling to cooperate participants;
* Participants have performed a surgery in the past 4 weeks;
* Participants with the tendency of bleeding or abnormal value of disseminated intravascular coagulation (DIC) or International standard ratio (INR) or thrombocytopenia patients;
* Participants have joined in other trial in the past 1 month;
* Participants allergic to the test drug, or people with allergic constitution;
* Participants with aphasia which affects data collection.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No